Loading...
•
Dec 31, 2021
Kodiak Sciences Q4 2021 Earnings Report
Announced fourth quarter and full year 2021 financial results, highlighting KSI-301's potential and progress in clinical trials.
Key Takeaways
Kodiak Sciences reported a net loss of $93.2 million for the fourth quarter of 2021, compared to a net loss of $46.6 million for the fourth quarter of 2020. The company ended the quarter with $731.5 million in cash and cash equivalents. The study did not meet its primary efficacy endpoint.
KSI-301 Phase 2b/3 pivotal study in wet AMD did not meet its primary efficacy endpoint.
Continued progress in ongoing KSI-301 pivotal program.
Company continued making substantial progress in commercial manufacturing capabilities in collaboration with its partner Lonza.
Company continued advancing pipeline product candidates KSI-501 and KSI-601.
Kodiak Sciences
Kodiak Sciences
Forward Guidance
Kodiak Sciences anticipates several upcoming events and milestones.
Positive Outlook
- Announce top-line data for BEACON, Phase 3 pivotal study of KSI-301 in RVO, 3Q 2022
- Complete enrollment in DAYLIGHT, short-interval pivotal study of KSI-301 in wet AMD, 1H 2022
- Mechanical completion of the Lonza-Kodiak Ibex Dedicate facility in 1H 2022
- Submit IND for KSI-501, a novel bispecific antibody biopolymer conjugate